Spectrum Pharmaceuticals, Inc. Says FDA Extends Review Date of Cancer Drug Published: Feb 23, 2009 Feb 23 (Reuters) - Spectrum Pharmaceuticals said U.S. regulators have extended the review date of its experimental cancer drug, Zevalin, to July 2. Related links Reuters This will open in a new window Email this Facebook Twitter LinkedIn Pinterest Reddit Back to news